• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.

作者信息

Newman J H, Wheeler L, Lane K B, Loyd E, Gaddipati R, Phillips J A, Loyd J E

机构信息

Center for Lung Research, Department of Medicine, Vanderbilt University School of Medicine, Nashville, TN, USA.

出版信息

N Engl J Med. 2001 Aug 2;345(5):319-24. doi: 10.1056/NEJM200108023450502.

DOI:10.1056/NEJM200108023450502
PMID:11484688
Abstract

BACKGROUND

Most patients with primary pulmonary hypertension are thought to have sporadic, not inherited, disease. Because clinical disease develops in only 10 to 20 percent of persons carrying the gene for familial primary pulmonary hypertension, we hypothesized that many patients with apparently sporadic primary pulmonary hypertension may actually have familial primary pulmonary hypertension.

METHODS

In a study conducted over 20 years, we developed a registry of 67 families affected by familial primary pulmonary hypertension. Through patient referrals, extensive family histories, and correlation of family pedigrees, we discovered shared ancestry among five subfamilies. We established the diagnosis of primary pulmonary hypertension by direct evaluation of patients and review of autopsy material and medical records. We assessed some family members for mutations in the gene encoding bone morphogenetic protein receptor II (BMPR2), which has recently been found to cause familial primary pulmonary hypertension.

RESULTS

We linked five separately identified subfamilies that included 394 known members spanning seven generations, which were traced back to a founding couple in the mid-1800s. Familial primary pulmonary hypertension has been diagnosed in 18 family members, 12 of whom were first thought to have sporadic disease. The conditions of 7 of the 18 were initially misdiagnosed as other cardiopulmonary diseases. Six members affected with familial primary pulmonary hypertension and 6 of 10 at risk for carriage have been undergone genotype analysis, and they have the same mutation in BMPR2, a transversion of thymine to guanine at position 354 in exon 3.

CONCLUSIONS

Many cases of apparently sporadic primary pulmonary hypertension may be familial. Failure to detect familial primary pulmonary hypertension results from incomplete expression within families, skipped generations, and incomplete family pedigrees. The recent discovery of mutations in BMPR2 should make it possible to identify those with susceptibility to disease.

摘要

相似文献

1
Mutation in the gene for bone morphogenetic protein receptor II as a cause of primary pulmonary hypertension in a large kindred.
N Engl J Med. 2001 Aug 2;345(5):319-24. doi: 10.1056/NEJM200108023450502.
2
Identification of a novel mutation in the gene for bone morphogenetic protein receptor II in an Israeli patient with familial primary pulmonary hypertension.在一名患有家族性原发性肺动脉高压的以色列患者中鉴定骨形态发生蛋白受体II基因的一种新突变。
Isr Med Assoc J. 2004 Mar;6(3):156-9.
3
Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia.遗传性出血性毛细血管扩张症患者肺动脉高压的临床和分子遗传学特征
N Engl J Med. 2001 Aug 2;345(5):325-34. doi: 10.1056/NEJM200108023450503.
4
Bone morphogenetic protein receptor-II mutation Arg491Trp causes malignant phenotype of familial primary pulmonary hypertension.骨形态发生蛋白受体-II突变Arg491Trp导致家族性原发性肺动脉高压的恶性表型。
Biochem Biophys Res Commun. 2004 Mar 19;315(4):1033-8. doi: 10.1016/j.bbrc.2004.01.158.
5
A novel mutation in the BMPR2 gene in familial pulmonary arterial hypertension.家族性肺动脉高压中BMPR2基因的一种新突变。
Chin Med J (Engl). 2008 Mar 5;121(5):399-404.
6
Mutations of the TGF-beta type II receptor BMPR2 in pulmonary arterial hypertension.转化生长因子-βⅡ型受体BMPR2突变与肺动脉高压
Hum Mutat. 2006 Feb;27(2):121-32. doi: 10.1002/humu.20285.
7
Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension.对骨形态发生蛋白受体 2(BMPR2)基因座的第二次遗传打击作为家族性肺动脉高压疾病进展调节因子的研究。
Circulation. 2005 Feb 8;111(5):607-13. doi: 10.1161/01.CIR.0000154543.07679.08.
8
[Clinical and genetic characteristics of a Chinese family of primary pulmonary hypertension].[一个中国原发性肺动脉高压家系的临床与遗传学特征]
Zhonghua Yi Xue Za Zhi. 2004 Feb 2;84(3):199-202.
9
[Bone morphogenetic protein type II receptor gene promoter mutation-142G > A in a patient with familial pulmonary arterial hypertension].[一名家族性肺动脉高压患者的骨形态发生蛋白II型受体基因启动子突变-142G>A]
Zhonghua Yi Xue Za Zhi. 2009 Feb 3;89(4):230-4.
10
BMPR2 mutations have short lifetime expectancy in primary pulmonary hypertension.骨形态发生蛋白受体2(BMPR2)突变在原发性肺动脉高压患者中的预期寿命较短。
Hum Mutat. 2005 Aug;26(2):119-24. doi: 10.1002/humu.20200.

引用本文的文献

1
The Interplay Between Pulmonary Hypertension and Atrial Fibrillation: A Comprehensive Overview.肺动脉高压与心房颤动之间的相互作用:全面概述
Cells. 2025 Jun 4;14(11):839. doi: 10.3390/cells14110839.
2
Decoding the enigmatic estrogen paradox in pulmonary hypertension: delving into estrogen metabolites and metabolic enzymes.解读肺动脉高压中神秘的雌激素悖论:深入探究雌激素代谢产物和代谢酶
Cell Mol Biol Lett. 2024 Dec 18;29(1):155. doi: 10.1186/s11658-024-00671-w.
3
John Newman, M.D. remembered.缅怀约翰·纽曼医生。
Pulm Circ. 2024 May 27;14(2):e12389. doi: 10.1002/pul2.12389. eCollection 2024 Apr.
4
Digital Spatial Profiling Identifies Distinct Molecular Signatures of Vascular Lesions in Pulmonary Arterial Hypertension.数字空间分析鉴定出肺动脉高压血管病变的独特分子特征。
Am J Respir Crit Care Med. 2024 Aug 1;210(3):329-342. doi: 10.1164/rccm.202307-1310OC.
5
The Cavin-1/Caveolin-1 interaction attenuates BMP/Smad signaling in pulmonary hypertension by interfering with BMPR2/Caveolin-1 binding.Cavin-1/窖蛋白-1 相互作用通过干扰 BMPR2/窖蛋白-1 结合来减弱肺动脉高压中的 BMP/Smad 信号传导。
Commun Biol. 2024 Jan 5;7(1):40. doi: 10.1038/s42003-023-05693-2.
6
Functions of RNA-Binding Proteins in Cardiovascular Disease.RNA 结合蛋白在心血管疾病中的功能。
Cells. 2023 Dec 8;12(24):2794. doi: 10.3390/cells12242794.
7
Human iPSCs as Model Systems for BMP-Related Rare Diseases.人诱导多能干细胞作为 BMP 相关罕见病的模型系统。
Cells. 2023 Sep 2;12(17):2200. doi: 10.3390/cells12172200.
8
Metabolic reprogramming, oxidative stress, and pulmonary hypertension.代谢重编程、氧化应激与肺动脉高压。
Redox Biol. 2023 Aug;64:102797. doi: 10.1016/j.redox.2023.102797. Epub 2023 Jun 24.
9
Multiomics Network Medicine Approaches to Precision Medicine and Therapeutics in Cardiovascular Diseases.多组学网络医学在心血管疾病精准医学和治疗中的应用。
Arterioscler Thromb Vasc Biol. 2023 Apr;43(4):493-503. doi: 10.1161/ATVBAHA.122.318731. Epub 2023 Feb 16.
10
Personalizing treatments for patients based on cardiovascular phenotyping.基于心血管表型为患者定制个性化治疗方案。
Expert Rev Precis Med Drug Dev. 2022;7(1):4-16. doi: 10.1080/23808993.2022.2028548. Epub 2022 Jan 24.